- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA Clears Updated DWI Software for Portable MRI Neuroimaging Device
The new software for the Swoop® Portable MR Imaging system reportedly enhances the signal-to-noise ratio for diffusion-weighted imaging (DWI) sequences by 42 percent in comparison to the previous software.
The Food and Drug Administration (FDA) has granted 510(k) clearance to new software for the Swoop® Portable MR Imaging device that may significantly enhance the quality of diffusion-weighted magnetic resonance imaging (MRI) for neurocritical patients.
The new software offers a 42 percent increase in the signal-to-noise ratio for diffusion-weighted imaging (DWI) sequences, according to Hyperfine, the manufacturer of the device. The company noted other benefits of the software include additional compensation for subtle patient movements and more uniform imaging for DWI sequences.
Emphasizing the key role DWI imaging plays in facilitating prompt diagnosis of an array of neurological conditions as well as the monitoring of stroke progression, Hyperfine said the updated software will provide a significant advance in care for high-risk populations.
“With this latest software, Swoop system images provide increasingly valuable diagnostic images that can aid clinicians in caring for neurocritical patients,” noted Edward Knopp, M.D., the senior medical director with Hyperfine.
Hyperfine received an FDA 510(k) clearance earlier this month for the device’s updated brain imaging software. The company said the updated DWI software will be available in March 2023.
(Editor’s note: For related content, see “Emerging Deep Learning System May Enhance MRI Assessment of Intracranial Tumors” and “FDA Clears AI-Enabled Software for Streamlining Brain MRI Assessment and Reporting.”)
Seven Takeaways from New CT and MRI Guidelines for Ovarian Cancer Staging
January 20th 2025In an update of previous guidelines from the European Society of Urogenital Radiology published in 2010, a 21-expert panel offered consensus recommendations on the utility of CT, MRI and PET-CT in the staging and follow-up imaging for patients with ovarian cancer.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.
